p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

Summary

This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start

2013-08

Primary completion

2015-04

Completion

2015-04

Drugs

Indications